Definium Therapeutics (DFTX) Assets Average (2022 - 2026)

Definium Therapeutics (DFTX) has 5 years of Assets Average data on file, last reported at $420.7 million in Q1 2026.

• On a quarterly basis, Assets Average rose 45.7% year-over-year to $420.7 million in Q1 2026; TTM through Mar 2026 was $420.7 million, a 45.7% increase from a year earlier, with the FY2025 full-year figure at $371.1 million, up 73.95% from the prior year.
• Assets Average for Q1 2026 stood at $420.7 million, up from $338.5 million in the prior quarter.
• Over the last five years, Assets Average for DFTX reached as high as $420.7 million in Q1 2026 and fell as low as $133.0 million in Q4 2023.
• Historically, Assets Average has averaged $227.3 million across 5 years, with a median of $200.0 million in 2024.
• Across the five-year window, Assets Average dropped 24.17% in 2023 and jumped 133.72% in 2024, its largest moves.
• Year by year, Assets Average stood at $175.4 million in 2022, then fell by 24.17% to $133.0 million in 2023, then soared by 133.72% to $311.0 million in 2024, then gained by 8.86% to $338.5 million in 2025, then advanced by 24.28% to $420.7 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $420.7 million in Q1 2026, $338.5 million in Q4 2025, and $251.0 million in Q3 2025.